Antiangiogenic plasma activity in patients with systemic sclerosis
β Scribed by Mary Jo Mulligan-Kehoe; Mary C. Drinane; Jessica Mollmark; Livia Casciola-Rosen; Laura K. Hummers; Amy Hall; Antony Rosen; Fredrick M. Wigley; Michael Simons
- Publisher
- John Wiley and Sons
- Year
- 2007
- Tongue
- English
- Weight
- 260 KB
- Volume
- 56
- Category
- Article
- ISSN
- 0004-3591
No coin nor oath required. For personal study only.
β¦ Synopsis
Abstract
Objective
Systemic sclerosis (SSc; scleroderma) is a systemic connective tissue disease with an extensive vascular component that includes aberrant microvasculature and impaired wound healing. The aim of this study was to investigate the presence of antiangiogenic factors in patients with SSc.
Methods
Plasma samples were obtained from 30 patients with SSc and from 10 control patients without SSc. The samples were analyzed for the ability of plasma to affect endothelial cell migration and vascular structure formation and for the presence of antiangiogenic activity.
Results
Exposure of normal human microvascular dermal endothelial cells to plasma from patients with SSc resulted in decreased cell migration (mean Β± SEM 52 Β± 5%) and tube formation (34 Β± 6%) compared with that in plasma from control patients (P < 0.001 for both). SSc plasma contained 2.9βfold more plasminogen kringle 1β3 fragments (angiostatin) than that in control plasma. The addition of angiostatin to control plasma resulted in inhibition of endothelial cell migration and proliferation similar to that observed in SSc plasma. In vitro studies demonstrated that granzyme B and other proteases contained in T cell granule content cleave plasminogen and plasmin into angiostatin fragments.
Conclusion
Plasminogen conformation in patients with SSc enables granzyme B and granule content protease to limit the proangiogenic effects of plasmin and increase the levels of antiangiogenic angiostatin. This increase in angiostatin production may account for some of the vascular defects observed in patients with SSc.
π SIMILAR VOLUMES
## Abstract ## Objective To assess health values in subjects with systemic sclerosis (SSc) and determine variability explained by demographics, clinical factors, health status, and disease severity. ## Methods We interviewed 107 individuals with SSc who attended national and local Scleroderma Fo
Objective. To determine the ability of T lymphocytes and natural killer (NK) cells from patients with systemic sclerosis (SSc) to respond to cytokines and to generate immune effector cells. Methods. The numbers and percentages of peripheral blood T and NK cells were examined by 2-color flow cytometr